Navigation Links
Former Senator Byron Dorgan Elected to Codexis Board
Date:2/17/2011

REDWOOD CITY, Calif., Feb. 17, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq: CDXS) today announced that Byron Dorgan, former U.S. Senator from North Dakota, has been elected to the company's Board of Directors. Senator Dorgan retired from the Senate in January 2011 after a 30-year career in the U.S. Congress.  

(Photo:  http://photos.prnewswire.com/prnh/20110217/SF50619)

"We are very pleased to welcome Byron Dorgan to our Board," said Alan Shaw, Ph.D., President and Chief Executive Officer.  "He is a champion of new technologies to enable innovation and has long advocated energy security through a comprehensive national energy policy. As Chairman of the Senate Energy and Water Appropriations Subcommittee, he worked to fund broad development of renewable energy sources. His substantial expertise will be valuable to Codexis."

Senator Dorgan served in the Senate leadership for 16 years, first as Assistant Democratic Floor Leader and then as Chairman of the Democratic Policy Committee. He was Chairman of the Senate Committees and Subcommittees on the issues of Appropriations, Commerce, Energy, Aviation, Water Policy, and Indian Affairs. First elected to Congress in 1980, Dorgan served six terms in the U.S. House of Representatives and three terms in the U.S. Senate. He was also North Dakota's youngest-ever constitutional officer when he was appointed State Tax Commissioner.

While in Congress, he built a reputation as a forward-looking energy policy maker, supporting the use of renewable energy and domestic energy sources, and moving away from a reliance on foreign oil.  He also emerged as one of the nation's leading voices on behalf of America's agriculture industry. He worked to expand North Dakota's burgeoning energy sector, preserve a strong safety net for family farmers, and spur economic development.

Senator Dorgan earned his Bachelor of Science degree from the University of North Dakota and his Master of Business Administration from the University of Denver.

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and in development for advanced biofuels with Shell and carbon capture with Alstom. Other potential markets for the company's biocatalyst-enabled solutions include chemicals and water treatment. For more information, see www.codexis.com.

Contact: Media; Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.  Investors; Robert Lawson, robert.lawson@codexis.com, 650-421-8137


'/>"/>
SOURCE Codexis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Former Speaker of the House Newt Gingrich Featured Wednesday
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Former Cables to Go/Lastar Inc. Employee's Move to Form American Consumer Cables Pays Off
4. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
5. Former Telomolecular CEO Clarifies SEC Settlement
6. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
7. Former NASDAQ International President Among Execs Launching Firm to Access Global Markets
8. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
9. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
10. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
11. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
Breaking Biology News(10 mins):